Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)
Abstract Introduction The Aiming High in Eczema/Atopic Dermatitis (AHEAD) guidelines recommend achieving minimal disease activity (MDA) in atopic dermatitis (AD), defined as simultaneous achievement of optimal treatment targets for at least one clinician- and one patient-reported outcome (ClinRO + P...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-07-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-025-01485-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849333662650204160 |
|---|---|
| author | Jonathan I. Silverberg Melinda Gooderham Norito Katoh Valeria Aoki Andrew E. Pink Yousef Binamer Brad Glick Petra Staubach Brian Calimlim Chao Li Ayman Grada Alvaro Moreira Wan-Ju Lee Andreas Wollenberg |
| author_facet | Jonathan I. Silverberg Melinda Gooderham Norito Katoh Valeria Aoki Andrew E. Pink Yousef Binamer Brad Glick Petra Staubach Brian Calimlim Chao Li Ayman Grada Alvaro Moreira Wan-Ju Lee Andreas Wollenberg |
| author_sort | Jonathan I. Silverberg |
| collection | DOAJ |
| description | Abstract Introduction The Aiming High in Eczema/Atopic Dermatitis (AHEAD) guidelines recommend achieving minimal disease activity (MDA) in atopic dermatitis (AD), defined as simultaneous achievement of optimal treatment targets for at least one clinician- and one patient-reported outcome (ClinRO + PRO). We assessed the effect of upadacitinib on achieving optimal ClinROs, optimal PROs, and MDA in Measure Up 1 (NCT03569293) and Measure Up 2 (NCT3607422) studies for patients with moderate to severe AD. Methods Patients were randomized to receive upadacitinib (15 mg or 30 mg) or placebo. Achievement of ≥ 1 optimal target in ClinROs, ≥ 1 optimal target in PROs, and MDA (≥ 1 optimal ClinROs and ≥ 1 optimal PROs) were reported at weeks 16 (upadacitinib vs placebo) and 52 (upadacitinib only). MDAs in selected combinations were also assessed at weeks 16 and 52. A total of 1683 and 1124 patients were included in the week 16 and 52 analysis, respectively. Results At week 16, a significantly higher proportion of patients receiving upadacitinib (15 mg: 42.5%, 30 mg: 55.9%) compared with placebo (6.4%) achieved MDA. At week 52, 57.4% and 69.9% of patients receiving 15 mg and 30 mg of upadacitinib achieved MDA, respectively. Specifically, patients receiving upadacitinib attained higher rates of ≥ 90% reduction from baseline in Eczema Area and Severity Index (EASI 90) + Worst Pruritus-Numerical Rating Scale (WP-NRS) 0/1 at week 16 (15 mg: 25.3%, 30 mg: 39.4% vs placebo: 1.8%) and maintained at week 52 (15 mg: 38.1%, 30 mg: 46.9%). Conclusion Treatment with upadacitinib achieved both ClinRO and PRO optimal treatment targets as well as MDA and may optimize overall disease management in patients with moderate-to-severe AD. |
| format | Article |
| id | doaj-art-e89be5ebf27c418594c6b6a2e12bba05 |
| institution | Kabale University |
| issn | 2193-8210 2190-9172 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj-art-e89be5ebf27c418594c6b6a2e12bba052025-08-20T03:45:47ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722025-07-011592583259410.1007/s13555-025-01485-0Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)Jonathan I. Silverberg0Melinda Gooderham1Norito Katoh2Valeria Aoki3Andrew E. Pink4Yousef Binamer5Brad Glick6Petra Staubach7Brian Calimlim8Chao Li9Ayman Grada10Alvaro Moreira11Wan-Ju Lee12Andreas Wollenberg13Department of Dermatology, The George Washington University School of Medicine and Health SciencesSKiN Centre for DermatologyNorth Campus, Kyoto Prefectural University of MedicineDepartment of Dermatology, Faculdade de Medicina, Universidade de São PauloSt John’s Institute of Dermatology, Guy’s & St Thomas’ NHS Foundation Trust and King’s College LondonDepartment of Dermatology, King Faisal Specialist Hospital & Research CentreGSI Clinical Research, LLCDepartment of Dermatology, University Medical Center of the Johannes Gutenberg-UniversityAbbVie IncAbbVie IncAbbVie IncAbbVie IncAbbVie IncDepartment of Dermatology and Allergy, University Hospital AugsburgAbstract Introduction The Aiming High in Eczema/Atopic Dermatitis (AHEAD) guidelines recommend achieving minimal disease activity (MDA) in atopic dermatitis (AD), defined as simultaneous achievement of optimal treatment targets for at least one clinician- and one patient-reported outcome (ClinRO + PRO). We assessed the effect of upadacitinib on achieving optimal ClinROs, optimal PROs, and MDA in Measure Up 1 (NCT03569293) and Measure Up 2 (NCT3607422) studies for patients with moderate to severe AD. Methods Patients were randomized to receive upadacitinib (15 mg or 30 mg) or placebo. Achievement of ≥ 1 optimal target in ClinROs, ≥ 1 optimal target in PROs, and MDA (≥ 1 optimal ClinROs and ≥ 1 optimal PROs) were reported at weeks 16 (upadacitinib vs placebo) and 52 (upadacitinib only). MDAs in selected combinations were also assessed at weeks 16 and 52. A total of 1683 and 1124 patients were included in the week 16 and 52 analysis, respectively. Results At week 16, a significantly higher proportion of patients receiving upadacitinib (15 mg: 42.5%, 30 mg: 55.9%) compared with placebo (6.4%) achieved MDA. At week 52, 57.4% and 69.9% of patients receiving 15 mg and 30 mg of upadacitinib achieved MDA, respectively. Specifically, patients receiving upadacitinib attained higher rates of ≥ 90% reduction from baseline in Eczema Area and Severity Index (EASI 90) + Worst Pruritus-Numerical Rating Scale (WP-NRS) 0/1 at week 16 (15 mg: 25.3%, 30 mg: 39.4% vs placebo: 1.8%) and maintained at week 52 (15 mg: 38.1%, 30 mg: 46.9%). Conclusion Treatment with upadacitinib achieved both ClinRO and PRO optimal treatment targets as well as MDA and may optimize overall disease management in patients with moderate-to-severe AD.https://doi.org/10.1007/s13555-025-01485-0Atopic dermatitisMinimal disease activityQuality of lifeClinician reported outcomePatient reported outcomeUpadacitinib |
| spellingShingle | Jonathan I. Silverberg Melinda Gooderham Norito Katoh Valeria Aoki Andrew E. Pink Yousef Binamer Brad Glick Petra Staubach Brian Calimlim Chao Li Ayman Grada Alvaro Moreira Wan-Ju Lee Andreas Wollenberg Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2) Dermatology and Therapy Atopic dermatitis Minimal disease activity Quality of life Clinician reported outcome Patient reported outcome Upadacitinib |
| title | Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2) |
| title_full | Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2) |
| title_fullStr | Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2) |
| title_full_unstemmed | Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2) |
| title_short | Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2) |
| title_sort | achieving optimal treatment targets and minimal disease activity with upadacitinib for moderate to severe atopic dermatitis integrated analysis of phase 3 studies measure up 1 and 2 |
| topic | Atopic dermatitis Minimal disease activity Quality of life Clinician reported outcome Patient reported outcome Upadacitinib |
| url | https://doi.org/10.1007/s13555-025-01485-0 |
| work_keys_str_mv | AT jonathanisilverberg achievingoptimaltreatmenttargetsandminimaldiseaseactivitywithupadacitinibformoderatetosevereatopicdermatitisintegratedanalysisofphase3studiesmeasureup1and2 AT melindagooderham achievingoptimaltreatmenttargetsandminimaldiseaseactivitywithupadacitinibformoderatetosevereatopicdermatitisintegratedanalysisofphase3studiesmeasureup1and2 AT noritokatoh achievingoptimaltreatmenttargetsandminimaldiseaseactivitywithupadacitinibformoderatetosevereatopicdermatitisintegratedanalysisofphase3studiesmeasureup1and2 AT valeriaaoki achievingoptimaltreatmenttargetsandminimaldiseaseactivitywithupadacitinibformoderatetosevereatopicdermatitisintegratedanalysisofphase3studiesmeasureup1and2 AT andrewepink achievingoptimaltreatmenttargetsandminimaldiseaseactivitywithupadacitinibformoderatetosevereatopicdermatitisintegratedanalysisofphase3studiesmeasureup1and2 AT yousefbinamer achievingoptimaltreatmenttargetsandminimaldiseaseactivitywithupadacitinibformoderatetosevereatopicdermatitisintegratedanalysisofphase3studiesmeasureup1and2 AT bradglick achievingoptimaltreatmenttargetsandminimaldiseaseactivitywithupadacitinibformoderatetosevereatopicdermatitisintegratedanalysisofphase3studiesmeasureup1and2 AT petrastaubach achievingoptimaltreatmenttargetsandminimaldiseaseactivitywithupadacitinibformoderatetosevereatopicdermatitisintegratedanalysisofphase3studiesmeasureup1and2 AT briancalimlim achievingoptimaltreatmenttargetsandminimaldiseaseactivitywithupadacitinibformoderatetosevereatopicdermatitisintegratedanalysisofphase3studiesmeasureup1and2 AT chaoli achievingoptimaltreatmenttargetsandminimaldiseaseactivitywithupadacitinibformoderatetosevereatopicdermatitisintegratedanalysisofphase3studiesmeasureup1and2 AT aymangrada achievingoptimaltreatmenttargetsandminimaldiseaseactivitywithupadacitinibformoderatetosevereatopicdermatitisintegratedanalysisofphase3studiesmeasureup1and2 AT alvaromoreira achievingoptimaltreatmenttargetsandminimaldiseaseactivitywithupadacitinibformoderatetosevereatopicdermatitisintegratedanalysisofphase3studiesmeasureup1and2 AT wanjulee achievingoptimaltreatmenttargetsandminimaldiseaseactivitywithupadacitinibformoderatetosevereatopicdermatitisintegratedanalysisofphase3studiesmeasureup1and2 AT andreaswollenberg achievingoptimaltreatmenttargetsandminimaldiseaseactivitywithupadacitinibformoderatetosevereatopicdermatitisintegratedanalysisofphase3studiesmeasureup1and2 |